Industry News
Pharmaceutical Industry News
Ahead of plans to raise the price…
Ahead of plans to raise the price of its Type 2 diabetes and obesity blockbuster in the United Kingdom next month, Eli Lilly is temporarily halting Mounjaro orders from the country.
For the second time, the FDA has…
For the second time, the FDA has declined to approve Outlook's anti-VEGF drug for the treatment of wet age-related macular degeneration.
Lawmakers in Virginia have…
Lawmakers in Virginia have approved proposed economic development packages for AstraZeneca and Eli Lilly to locate new manufacturing facilities in the state, according to a report in the Richmond Times-Dispatch.
Fresenius and Charles River…
Fresenius and Charles River Laboratories are among 18 partners that have formed a European Union-supported consortium to develop an automated, hospital-based manufacturing platform for CAR-T therapies.
Roche’s U.S. subsidiary…
Roche’s U.S. subsidiary Genentech broke ground Monday on a $700 million plant tabbed for operation in 2029. The fill-finish plant, which will help produce obesity drugs, is part of Roche’s plan to invest $50 billion
FDA Approves Updated Covid Vaccines With New Restrictions
The agency’s fall recommendations underscore the goals of Health Secretary Robert F. Kennedy Jr. to limit access to the vaccines, which he has long opposed.
What to Know About Covid Vaccines This Fall
The F.D.A. introduced new rules. Here’s what to know.
On the Health Matters podcast,…
On the Health Matters podcast, Gottlieb weighs in on affordability, policy shifts and the future of medical breakthroughs.
Artificial intelligence (AI) has…
Artificial intelligence (AI) has quickly moved beyond being a buzzword in healthcare marketing—it’s now powering real change. In the latest episode of The Next Marketing with HJ, Harshit Jain (HJ), Founder & Global CEO of
Amid uncertainty over how the…
Amid uncertainty over how the Trump administration would approach mRNA vaccines for the upcoming COVID-19 season, the FDA has approved updated shots from Pfizer and Moderna. But rather than granting the broad approvals the vaccines
The company’s three-prong…
The company's three-prong "Indivior Action Agenda" is all meant to boost U.S. growth of opioid use disorder treatment Sublocade.
A newly published report developed…
A newly published report developed by a group of partners, including Sanofi, shines a light on the far-reaching impacts of well-funded community health worker programs.
China biotech RemeGen and its new…
China biotech RemeGen and its new U.S. partner Vor Bio are on a roll with their first-in-class autoimmune treatment telitacicept. Two weeks after revealing the success of a phase 3 trial of telitacicept in Sjögren’s disease,
Eli Lilly’s Verzenio has proven…
Eli Lilly’s Verzenio has proven its ability to prolong the lives of patients with HR-positive, HER2-negative, node-positive high-risk early breast cancer, the company said Wednesday.
A new report from MassBio suggests…
A new report from MassBio suggests the state isn’t immune to the funding slowdowns and policy shifts that have put pressure on the industry over the past year and a half.
Phreesia is bringing Sesame Street…
Phreesia is bringing Sesame Street to the doctor’s office. The patient activation company has partnered with the nonprofit behind the TV show to work characters such as Elmo and Cookie Monster into joint campaigns aimed
For the third year in a row,…
For the third year in a row, Cleveland Diagnostics is commemorating September’s Prostate Cancer Awareness Month with its “A PSA on PSA” campaign that serves as a public service announcement about prostate-specific antigen testing.
Curious where audio in pharma is…
Curious where audio in pharma is headed? Discover the trends driving this season’s planning and innovation conversations.
The deal will bring together…
The deal will bring together Waltz's proprietary drug marketplaces and direct-to-payer model with Eversana's global pharmaceutical commercialization platform.
Akeso and Summit Therapeutics’…
Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody has shown for the first time that it can extend patients’ lives. The result comes from a China-only phase 3 trial in certain patients with lung